Best response observed among the 51 eligible patients receiving VAC plus valproic acid in refractory/relapsing small cell lung cancer

Type of responseSubjects n
Complete response0
Partial response10
No change5
Early death due to cancer2
Early death due to toxicity1
High toxicity2
Not evaluable3
  • VAC: doxorubicin, vindesine and cyclophosphamide.